CpG methylation analysis - Current status of clinical assays and potential applications in molecular diagnostics: A report of the association for molecular pathology Journal Article
| Authors: | Sepulveda, A. R.; Jones, D.; Ogino, S.; Samowitz, W.; Gulley, M. L.; Edwards, R.; Levenson, V.; Pratt, V. M.; Yang, B.; Nafa, K.; Yan, L.; Vitazka, P. |
| Article Title: | CpG methylation analysis - Current status of clinical assays and potential applications in molecular diagnostics: A report of the association for molecular pathology |
| Abstract: | Methylation of CpG islands in gene promoter regions is a major molecular mechanism of gene silencing and underlies both cancer development and progression. In molecular oncology, testing for the CpG methylation of tissue DNA has emerged as a clinically useful tool for tumor detection, outcome prediction, and treatment selection, as well as for assessing the efficacy of treatment with the use of demethylating agents and monitoring for tumor recurrence. In addition, because CpG methylation occurs early in pre-neoplastic tissues, methylation tests may be useful as markers of cancer risk in patients with either infectious or inflammatory conditions. The Methylation Working Group of the Clinical Practice Committee of the Association of Molecular Pathology has reviewed the current state of clinical testing in this area. We report here our summary of both the advantages and disadvantages of various methods, as well as the needs for standardization and reporting. We then conclude by summarizing the most promising areas for future clinical testing in cancer molecular diagnostics. Copyright © American Society for Investigative Pathology and the Association for Molecular Pathology. |
| Keywords: | cancer chemotherapy; treatment response; acute granulocytic leukemia; methylation; review; cancer growth; pancreas cancer; temozolomide; cancer diagnosis; neoplasm; colorectal cancer; quality control; cytology; diagnostic procedure; infection; breast cancer; alkylating agent; cyclophosphamide; validation study; assay; prediction; urogenital tract cancer; standardization; b cell lymphoma; myelodysplastic syndrome; cpg island; screening; quantitative analysis; glioblastoma; lymphoma; restriction endonuclease; 5 aza 2' deoxycytidine; cancer epidemiology; methylated dna protein cysteine methyltransferase; diagnostic test; urinalysis; tumor growth; cancer classification; decision making; bacterial infection; virus; esophagus carcinoma; azacitidine; uterine cervix carcinoma; body fluid; bile duct cancer; qualitative analysis; bisulfite; inflammatory disease |
| Journal Title: | Journal of Molecular Diagnostics |
| Volume: | 11 |
| Issue: | 4 |
| ISSN: | 1525-1578 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2009-07-01 |
| Start Page: | 266 |
| End Page: | 278 |
| Language: | English |
| DOI: | 10.2353/jmoldx.2009.080125 |
| PROVIDER: | scopus |
| PMCID: | PMC2710701 |
| PUBMED: | 19541921 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 3" - "Export Date: 30 November 2010" - "CODEN: JMDIF" - "Source: Scopus" |
